China
Africa
Explore chapters and articles related to this topic
Polypoidal Choroidal Vasculopathy
Published in Ching-Yu Cheng, Tien Yin Wong, Ophthalmic Epidemiology, 2022
Polypoidal choroidal vasculopathy (PCV) was first described by Yannuzzi in 1982, as “idiopathic polypoidal choroidal vasculopathy.”1 PCV shares similarities with neovascular age-related macular degeneration (nAMD), i.e., PCV typically evokes recurrent exudative changes and subretinal or sub-retinal pigment epithelial (RPE) bleeding in the macula, resulting in subretinal fibrosis if left untreated. It sometimes causes massive subretinal hemorrhage or vitreous hemorrhage, which may result in severe loss of vision.
Comparison of Regional Differences in the Choroidal Thickness between Patients with Pachychoroid Neovasculopathy and Classic Exudative Age-related Macular Degeneration
Published in Current Eye Research, 2021
Young Ho Kim, Boram Lee, Edward Kang, Jaeryung Oh
In this retrospective study, we reviewed consecutive patients with MNV from the SS-OCT database between March 2016 and December 2019 who were seen at Korea University Medical Center. We only included patients older than 50 years who had unilateral MNV due to ceAMD or PNV. We also included normal subjects with normal fundus as a normal control group. Patients with advanced AMD in both eyes and patients with polypoidal choroidal vasculopathy (PCV) in either eye were excluded. In addition, we excluded eyes with prior anti-vascular endothelial growth factor (anti-VEGF) therapy due to other cause such as central serous chorioretinopathy within the last 6 months. Other exclusion criteria were as follows: 1) patients with high myopia (axial length ≥ 28.0 mm); 2) patients with geographic atrophy or disciform scarring; 3) prior history of photodynamic therapy and laser photocoagulation; 4) history of glaucoma, refractive or vitreoretinal surgery; and 5) history of cataract surgery in the 6 months prior to thickness evaluation; 6) history of optic nerve disorders, vascular disease, uveitis, use of diuretics; and 7) patients with diabetic macular edema and diabetic retinopathy that complicate the evaluation of images.
Analysis of Choroidal Thickness in Children with Congenital Aniridia
Published in Current Eye Research, 2020
Hui Chen, Xiaohang Wu, Xiaoyan Li, Jingjing Chen, Zhuoling Lin, Weirong Chen, Haotian Lin
The choroid is the most vascular structure in the eye and serves as the oxygen and nutrient supply to the outer retina, RPE and the optic nerve.8 As such choroidal vessels of normal structure and function are essential for retinal function. Abnormal choroidal vasculature may result in various ocular diseases such as polypoidal choroidal vasculopathy, central serous chorioretinopathy, Vogt-Koyanagi-Harada and others.9–11 The choroid lies between the rigid sclera and RPE, therefore quantitative assessment of the choroid is difficult. Recently, optical coherence tomography (OCT) was widely applied to clinically assess the choroidal vasculature in vivo, which enables the analysis of the morphology of the choroid and the manual assessment of the choroidal vasculature with custom software.12 Analysis of individual choroidal thicknesses (CTs) may help to determine the structural changes associated with aniridia. We assumed that the CTs of aniridic eyes may be thinner than that in healthy eyes; however, this assumption needs to be demonstrated. The present study evaluated the CTs in children with congenital aniridia, and the results were compared with the findings for healthy controls.
Long-Term Changes in Submacular Choroidal Thickness after Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration: 14-Mo Follow-Up
Published in Current Eye Research, 2019
Sibel Inan, Zeki Baysal, Umit Ubeyt Inan
Exclusion criteria comprised CNV secondary to conditions other than AMD (e.g., angioid streaks; pathological myopia; presumed histoplasmosis; idiopathic and/or inflammatory CNV; absence of evidence of subfoveal involvement; extremely late-stage disease (e.g., disciform scarring of >50% of the lesion area), and/or VA<20/200; spherical refractive errors >3.0 diopters (D) related to axial length (AL) in phakic eyes; any sign of retinal pathological myopia in pseudophakic eyes11,21; any previous treatments for exudative AMD (e.g., photodynamic therapy or any intravitreal injections); any media opacity preventing acquisition of suitable images; glaucoma; ocular inflammatory conditions; concomitant ocular diseases that might further compromise VA or affect choroidal thickness (e.g., epiretinal membrane, diabetic retinopathy, retinal venous occlusion, history of intraocular surgery within the past 6 mo, aphakia, absence of posterior capsule, or history of vitrectomy attributable to reduced ranibizumab retention); systemic contraindications for anti-VEGF treatment; retinal angiomatous proliferation; and polypoidal choroidal vasculopathy. No eyes with polypoidal choroidal vasculopathy or retinal angiomatous proliferation were included in our study. Data regarding duration of disease, number of intravitreal anti-VEGF injections, VA, lens status, and concomitant pathologic retinal features observed during follow-up were recorded.